Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

Boston-based #biotech #AvalynPharma is the latest to hop on the #IPO train, filing to list on the #Nasdaq and raise funds for late-stage clinical development of its inhaled therapies for #pulmonaryfibrosis (PF).

Avalyn Pharma Files S-1 for U.S. IPO Avalyn Pharma filed a Form S-1 on Apr 8, 2026 (reported Apr 9, 2026); SEC review typically 30–90 days and lockups commonly run 180 days.

Avalyn Pharma Files S-1 for U.S. IPO: Avalyn Pharma filed a Form S-1 on Apr 8, 2026 (reported Apr 9, 2026); SEC review typically 30–90 days and lockups commonly run 180 days. 👈 Read full analysis #AvalynPharma #IPO #Investment #Finance #StockMarket

Additional $$$ Raises: #AvalynPharma $100M Series D; #Bowtie $70M Series C; #Makersite €60M Series B; #PanaceaFinancial $62M Series B; #Lumotive $59M Series B; #Buena $58M; #EtonSolutions $58M Series C; #Guardz $56M Series B; #antheia $56M Series C; #CloudZero $56M Series C

Qureight and Avalyn launch strategic partnership in pulmonary fibrosis - PharmaTimes Partnership aims to leverage cutting-edge technology in clinical trials

#Qureight #pulmonaryfibrosis #fibroticlungdiseases #QureightLtd #AvalynPharma #progressivepulmonaryfibrosis #PPF #MISTstudy #AP01 #inhaledpirfenidone #PPFpatients #deeplearning #AI #imagingtechnologies #CoreImagingPlatformtechnology #fibrosis
pharmatimes.com/news/qureigh...